Novel Antibody-Drug Conjugate Under Study in Platinum-Sensitive Ovarian Cancer
Posted: Monday, August 10, 2020
Combination treatment of the antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) with carboplatin may be an effective alternative therapy for patients with recurrent platinum-sensitive ovarian cancer, according to a study published in Gynecologic Oncology. In addition, administration of bevacizumab with this combination therapy did not alter therapeutic outcomes. Overall, this immunochemotherapy regimen was reported to be safe and tolerable in study patients, according to Joyce F. Liu, MD, MPH, of the Dana-Farber Cancer Institute, Boston, and colleagues.
From 2013 to 2015, a total of 41 patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer were enrolled in the open-label, multicenter phase Ib study. All patients had radiographic disease progression or relapse within 6 to 18 months after completing platinum-based chemotherapy. All patients were intravenously administered 1.2 mg/kg of lifastuzumab vedotin once every 3 weeks in a 3+3 dose-escalation scheme. In addition, all patients were given AUC 6 of carboplatin every 3 weeks. Patients were divided into two cohorts: cohort A received an additional 15 mg/kg of bevacizumab (n = 12), and cohort B did not.
The recommended therapeutic dose was 2.4 mg/kg of lifastuzumab vedotin plus carboplatin AUC 6, with or without 15 mg/kg of bevacizumab. Their findings also revealed the median progression-free survival for patients to be 10.7 months. Moreover, all patients experienced at least one treatment-related adverse event including neutropenia, peripheral neuropathy, thrombocytopenia, nausea, fatigue, anemia, diarrhea, vomiting, hypomagnesemia, increased aspartate and alanine aminotransferase, and alopecia. A total of 83% of patients experienced more than three treatment-related adverse events.
“Based on the cumulative experience with the three lifastuzumab vedotin antibody-drug conjugate study drug trials…, it is proposed that both response rate and duration of response will be important factors in evaluating the activity of antibody-drug conjugates in ovarian cancer in future studies,” the authors concluded.
Disclosure: For full disclosures of the study authors, visit gynecologiconcology-online.net.
